Compare · CLYM vs NVO
CLYM vs NVO
Side-by-side comparison of Climb Bio Inc. (CLYM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLYM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 297.0x CLYM ($616.7M).
- Over the past year, CLYM is up 709.0% and NVO is down 45.7% - CLYM leads by 754.7 points.
- CLYM has been more active in the news (13 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for CLYM).
- Company
- Climb Bio Inc.
- Novo Nordisk A/S
- Price
- $10.76+1.99%
- $41.01-4.51%
- Market cap
- $616.7M
- $183.15B
- 1M return
- -9.73%
- -10.44%
- 1Y return
- +709.02%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 13
- 8
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CLYM
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- SEC Form 4 filed by Director Levin Andrew David
- SEC Form 4 filed by Director Drapkin Kimberlee C
- SEC Form 4 filed by Director Williams Douglas E
- SEC Form 4 filed by Director Cumbo Alexander
- SEC Form 4 filed by Director Thomas Stephen Basil
- SEC Form 4 filed by Director Dunn Judith
- SEC Form 8-K filed by Climb Bio Inc.
- Guggenheim initiated coverage on Climb Bio with a new price target
- SEC Form 8-K filed by Climb Bio Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care